Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts

Tropical Medicine and International Health

Volumn 4, Issue 6, 1999, Pages 412-420

  Trouiller, P ^a,b   Battistella, C ^a   Pinel, J ^a   Pecoul, B ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Clinical trial; Orphan drug; Pharmaceutical research and development; Rare disease; Tropical diseases

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B; ARTEMISININ DERIVATIVE; ATOVAQUONE; BENZNIDAZOLE; ESSENTIAL DRUG; HALOFANTRINE; IVERMECTIN; MEFLOQUINE; ORPHAN DRUG; OXAMNIQUINE; PENTAMIDINE; PRAZIQUANTEL;

AFRICAN TRYPANOSOMIASIS; ARTICLE; DRUG INDICATION; DRUG MARKETING; EUROPE; HUMAN; LAW; MALARIA; TROPICAL DISEASE;

EUROPE; HUMANS; MALARIA; ORPHAN DRUG PRODUCTION; PHARMACOLOGY; TROPICAL MEDICINE; TRYPANOSOMIASIS, AFRICAN; UNITED STATES;

EID: 0032791853     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.1999.00420.x     Document Type: Article

References (28)

1. Anonymous (1995) Buying into the orphan drug marker. Lancet 346, 917.
2. Barrett MP (1999) The fall and rise of sleeping sickness. Lancet 353, 1113-1114.
3. DiMasi J, Seibring MA, & Lasagna L. (1994) New drug developments in the United States from 1963 to 1992. Clinical Pharmacology and Therapeutics, 55, 609-622.
4. European Union (1998) Proposition de Règlement (CF.) du Parlement européen et du Conseil concernant les médicaments orphelins. Available from: URL: http://dg3.eudra.org/.
5. Grabowski H (1997) The effect of pharmacoeconomics on company research and development decisions. Pharmacoeconomics 5, 389-397.
6. Grabowski H & Vernon JM (1994) Returns to R & D on new drug introduction in the 1980s. Journal of Health Economics 13, 383-406.
7. Haffner M (1994) Orphan products. Ten years later and then some. Food and Drug Law Journal 49, 593-601.
8. Haffner M (1998) Orphan drug development. International program and study design issues. Drug Information Journal 32, 93-99.
9. Journal Officiel (UE) Assemblée Afrique Caraibes Pacifique-Union Européenne: Résolution relative aux médicaments orphelins. 20 mars (1997) ACP-EU/2098/97. Journal of O N C 308, 9/10/1997.
10. Levine M & Levine O (1997) Influence of disease burden, public perception and other factors on new vaccine development, implementation and continued use. Lancet 350, 1386-1392.
11. Love J (1992) The Orphan Drug Act and Government sponsored monopolies for marketing pharmaceutical drugs. Comments submitted to the Subcommittee on Antitrust, Monopolies and Business Rights of the Committee on the Judiciary, January 21, 1992. United States Senate, Washington DC.
12. Love J (1997) Call for more reliable costs data on clinical trials. Marketletter January 13, 1997, 24-25.
13. Mackay J (1993) The state of health. Simon & Schuster, New York.
14. Mesle F & Vallin J (1995) La mortalité, dans le monde: tendances et perspectives. Les Dossiers du CEPED. Paris, 30, 12-15.
15. O'Brien P (1998) The normalisation of the international market for pharmaceuticals: future impacts in emerging markets. In Medicines and the New Economic Environment (eds. F Lobo & G Velasquez) Biblioteca Civitas Economica Y Empresa, Madrid, pp. 77-97.
16. Olliaro P (1997) Will the fight against tropical diseases benefit from orphan drug status? Tropical Medicine and International Health 2, 113-115.
17. Pécoul B, Chirac P, Trouiller P & Pinel J (1999) Access to essential drugs in poor countries. A lost battle? Journal of the American Medical Association 281, 361-367.
18. Public Law (1983) United States Federal Food, Drug and Cosmetic Act - Orphan Drug Act. PL 97-414, January 4.
19. Reich M (1998) International strategies for tropical disease treatments: Experiences with Praziquantel. WHO/DAP/CTD/98.5, World Health Organisation, Geneva.
20. Richardson DM (1987) The orphan drug tax credit: an inadequate response to an ill-defined problem. The American Journal of Tax Policy 6, 135-210.
21. Sykes R (1998) The contribution of the research-based pharmaceutical industry. World Health Organisation and International Federation of Pharmaceutical Manufacturers Association round-table. Proceedings 1998 October 21; WHO, Geneva.
22. Trouiller P (1996) Recherche et développements pharmaceutiques en matière de maladies transmissibles dans la zone intertropicale. Cahiers Santé 6, 299-307.
23. Trouiller P, Battistella C, Szumilin E & Pinel J (1998) Are tropical diseases rare diseases? Médecins Sans Frontières, Paris.
24. Trouiller P & Olliaro P (1998) Orphan drug legislations: what is left for tropical diseases? Proceedings of the Workshop Workshop on Rare Diseases and Orphan Drugs. European perspective, European Foundation for the Advancement of Medicine; 1998 May 5, Brussels, Belgium.
25. Trouiller P & Olliaro P (1999) Drug development output during 1975-96: what proportion for tropical diseases? International Journal of Infectectious Diseases 3, 61-63.
26. US Congress, Office of Technology Assessment (1993) Pharmaceutical R & D: costs, risks and rewards. Federal support for pharmaceutical research and development. OTA-H-522, US Government Printing office, Washington DC, pp. 201-235.
27. US Senate (1992) Orphan drug amendments of 1992, report of the Committee on Labor and Human Resources. US Senate, Washington DC, no 102-358.
28. Wolf A (1994) Les orphelins de la santé. INSERM, Paris, p. 26.